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Amitriptyline is a pleiotropic tricyclic antidepressant, which
has anti-oxidant and anti-inflammatory properties. We tested
whether amitriptyline might be useful in the treatment of
chronic renal disease using the mouse model of unilateral
ureteral obstruction. Amitriptyline caused a significant
reduction of interstitial fibrosis, determined by Masson’s
staining, with minimal myofibroblast formation and
macrophage infiltration following ureteral obstruction. Using
quantitative PCR we found that this treatment significantly
reduced the expression of key molecular markers of
progressive tubulointerstitial injury such as osteopontin,
MCP-1, ICAM-1, and TGF-b1 compared to their level in a
saline-treated control group. Sublethal X-irradiation or
mycophenolate mofetil, treatments that reduce
inflammation, were comparable to amitriptyline in the
reduction of interstitial fibrosis and macrophage infiltration.
These studies in animals suggest that amitriptyline is worth
testing as a therapeutic agent that might preserve renal
function by blocking inflammation and renal fibrosis.
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Renal tubulointerstitial fibrosis is a common feature of
chronic renal disease,1,2 characterized by epithelial–mesench-
ymal transdifferentiation, accumulation of extracellular
matrix, and mononuclear infiltration, leading to tubular cell
loss and inflammation.2,3 Unilateral ureteral obstruction
(UUO) is a representative model of tubule interstitial renal
fibrosis and inflammation, characterized by cellular and
molecular events,4,5 such as significant interstitial inflamma-
tory cell infiltration, tubulointerstitial fibrosis, release of
transforming growth factor-b1 (TGF-b1), upregulation of
monocyte chemoattractant peptide (MCP-1),6,7 osteopon-
tin,8 and intercellular adhesion molecule 1 (ICAM-1).9
Several drugs have been studied so far to ameliorate or
even abolish interstitial fibrosis and inflammation during the
progression of renal disease.5,10–12 Attempts to avoid
tubulointerstitial inflammation by imunosupression were
successful to inhibit renal fibrosis. Rapamycin and myco-
phenolate mofetil (MMF), immunosuppressive agents, were
described to improve the progression of injury elicited by
UUO. However, cost and adverse effects caused difficulty in
the establishment of an efficient therapy based on that
approach.
Data from our group demonstrated that amitriptyline
(AMT), a drug commonly used for many years for the
treatment of depression and other conditions, facilitates the
elimination of urinary calculi in felines and significantly
ameliorates their renal function.13 Although AMT is classified
as a tricyclic antidepressant, its full range of actions is not
fully known and not attributable solely to its antidepressant
actions. AMT treatment reduces the pain caused by
peripheral-nerve disease14 and is also a potent H-1 receptor
blocker that inhibits the release of histamine from mast cells
in vitro.15 In humans, analgesic effects of AMT were also
associated to inhibition of noradrenaline and serotonin
reuptake.16 Additional benefits of AMT have been described
in interstitial cystitis17,18 and idiopathic cystitis.19 Its role in
inflammation has been addressed20 and Obuchowicz et al.21
showed that AMT alters cytokine activity, inhibiting the
release of proinflamatory interleukin-1, whereas others
described its effect increasing the release of immunosuppres-
sive and anti-inflammatory interleukin-10.22 AMT exhibits
antioxidant properties per se,23 inhibits natural killer cell
activity24 as well as nitric oxide, prostaglandin E2, and
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hialuronic acid production.25 Taken together, these studies
clearly demonstrate that AMT may have pleiotropic effects.
This study is the first attempt to examine the patho-
physiological significance of AMT administration in a model
of kidney disease. Based on literature data, we hypothesized
that administration of AMT in vivo might ameliorates renal
tubulointerstitial fibrosis after UUO.
RESULTS
Amitriptyline reduces interstitial fibrosis and macrophage
influx after UUO
Nonobstructed contralateral kidneys from mice of both
groups (UUO and UUOþAMT) did not show any
morphological, cellular, or molecular alteration (data not
shown). Kidneys from mice subjected to ureteral obstruction
developed a severe tubulointerstitial injury consisting of
tubular dilatation and atrophy, interstitial inflammation, and
a marked interstitial fibrosis, characterized by interstitial
extracellular matrix deposition. Glomeruli and vessels were
well preserved. Analysis of interstitium by Masson’s tri-
chrome staining showed that UUO promoted intense
deposition of extracellular matrix and consequently changes
in renal morphology due to interstitial fibrosis. AMT
administration attenuated interstitial fibrosis induced by
UUO, preserving tubular morphology (Figure 1).
We also analyzed expression of key markers during the
course of renal damaged induced by UUO. It is well described
that following ureteral obstruction, tubular epithelial cells
undergo epithelial–mesenchymal transdifferentiation, acquir-
ing myofibroblast phenotype. This was assessed by immuno-
histochemical detection of aSMA, a marker of interstitial
myofibroblast differentiation. Contralateral kidneys normally
express aSMA of renal arterioles and mesangial cells inside
glomeruli, and that was not influenced by UUO. Ureteral
obstruction promoted an increase in the expression of aSMA
starting 1 day after the procedure. Strong expression was
observed 3 days after ureteral obstruction, maintained at
high levels during the course of 10 days after the procedure.
AMT administration significantly attenuated epithelial–
mesenchymal transdifferentiation after UUO (Figure 2), with
minimal aSMA expression observed after 1 and 3 days of
intervention. Although an increased signal was observed 5
days after UUO, that was totally reversed at the end of 10
days, when aSMA expression and renal morphology was
similar to contralateral kidneys and localized mainly in
glomeruli and vessels (Figure 2).
Another key feature of ureteral obstruction injury is
intense inflammatory response due to macrophage infiltra-
tion. Contralateral kidneys did not present any significant
signal for macrophage infiltration, assessed by CD68
immunohistochemistry. As expected, ureteral obstruction in
nontreated mice induced a severe interstitial inflammation
due to macrophage infiltration in periglomerular and
peritubular interstitium, which presented maximum signal
at 5 days after the ureteral ligation, and was maint-
ained intense after 10 days (Figure 3). Surprisingly, AMT
administration promoted a significant effect, reducing
macrophage infiltration and preventing interstitial inflam-
mation (Figure 3). We observed CD68 staining only in a few
periglomerular areas 5 days after ligation. However, the net
effect of AMT administration was a significant inhibition of
interstitial inflammation and preservation of renal morphol-
ogy after ureteral obstruction.
Renal expression of TGF-b1, osteopontin, MCP-1, and ICAM-1
was attenuated by amitriptyline after UUO
As we observed inhibition of inflammatory response after
AMT administration in UUO model, we proposed that AMT
could attenuate renal injury induced by ureteral obstruction
through inhibition of genes involved in development and
progression of interstitial fibrosis. As demonstrated in Figure
4a, obstructed kidneys significantly express high levels of
TGF-b1 (11.5±1.0 fold change at day 5, N¼ 6). Adminis-
tration of AMT reduced the expression of that profibrogenic
cytokine (3.1±1.1 fold change at day 5, N¼ 6, Po0.05).
Several mechanisms seemed to be related to the reduction
of macrophage infiltration. To better understand the
mechanisms of AMT blockade on interstitial inflammation,
we examined the mRNA levels of the typical macrophage
chemokines osteopontin, MCP-1, and ICAM-1 by quantita-
tive real-time PCR (qPCR).
As seen in Figure 4b, UUO promoted a significant time-
dependent increase in osteopontin mRNA expression (max-
imum expression at day 5, 34.6±2.0 fold change, N¼ 6) and
that was suppressed by AMT treatment (6.7±0.9 fold change
at day 5, N¼ 6, Po0.01). In our experimental model, UUO
promoted a 40.5±1.5 and 60.1±2.8 fold change increase at
days 5 and 10 (N¼ 6), respectively. AMT treatment decreased
MCP-1 expression at day 5 (15.3±1.1 fold change, N¼ 6,
Po0.05) and almost abolished it at day 10 (5.0±0.5 fold
change, N¼ 6, Po0.01), which could explain the effect of
AMT in the inhibition of macrophage infiltration (Figure 3).
AMT treatment also promoted a significant inhibition of
ICAM-1 gene expression after ureteral obstruction (18.5±0.5
fold change in UUO group vs 4.1±1.2 fold change in AMT
group at day 5, N¼ 6, Po0.05).
Comparison of AMT, mycophenolate mofetil, or X-irradiation
on progression of renal injury triggered by UUO
To compare the effects of AMT treatment with other
therapies suitable to suppress the inflammatory response
observed during renal injury triggered by UUO, we employed
the imunossupressor MMF and whole body X-irradiation
(Xi). As demonstrated in Figure 5 and Table 1, MMF and Xi
were able to inhibit (SMA expression 5 days after UUO.
These results demonstrate the efficacy of both therapies to
prevent epithelial-mesenchymal transition (EMT) and con-
sequently interstitial fibrosis during the injury. Data from
MMF and Xi therapy are also comparable to that acquired
after administration of AMT, which reinforces the possible
use of AMT to treat fibrotic renal injury. When we analyze
the inflammatory process triggered UUO, due to macrophage
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infiltration, the suppression induced by MMF and Xi were
effective to avoid immune cell migration to injury site
(Figure 6 and Table 2). None or few anti-CD68 stains can be
observed in samples from UUOþMMF or UUOþXi after 5
days. A weak signal is observed in AMT-treated obstructed
kidneys, demonstrating that all therapies employed were
efficient in avoiding tubulointerstitial fibrosis and inflamma-
tion.
We also tested the effects of all therapies (AMT, MMF, or
Xi) on expression of genes involved in fibrosis development
and tubulointerstitial inflammation in the UUO model, as
described above. As demonstrated in Figure 7a, MMF was
Contralateral UUO UUO + AMT
Figure 1 | Interstitial renal fibrosis. Sections of contralateral kidneys, nontreated obstructed kidneys (UUO), and amitriptyline-treated
obstructed kidneys (UUOþAMT), stained with the Masson’s trichrome stain, 5 days after the procedure. Each image was randomly acquired
from the cortex area and is representative for 5 animals. Original magnification  200.
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Figure 2 | a-Smooth muscle actin expression. Representative interstitial a-smooth muscle actin expression in contralateral kidneys,
nontreated obstructed kidneys (UUO), and amitriptyline-treated obstructed kidneys (UUOþAMT) after 1, 3, 5, or 10 days of the procedure.
Each image was randomly acquired from the cortex area and is representative for five animals. Original magnification  200.
598 Kidney International (2009) 75, 596–604
o r i g i n a l a r t i c l e E Achar et al.: Amitriptyline ameliorates UUO
able to significantly inhibit TGF-b1 expression 5 days after
the procedure (3.9±0.4 fold change, N¼ 5, Po0.05). Similar
results were obtained in Xi-obstructed kidneys (6.6±0.2 fold
change at day 5, N¼ 5, Po0.05). When compared to
AMT-treated obstructed kidneys data, TGF-b1 expression
was lower than other therapies, suggesting that maybe AMT
could present the best result in an attempt to inhibit TGF-b1.
However, no statistically significant differences were observed
between treatments (P¼ 0.292). Analysis of osteopontin
expression (Figure 7b) revealed the same pattern obtained
for TGF-b1: MMF and Xi-inhibited osteopontin mRNA
levels (21.6±0.9 and 13.4±1.6 fold change at day 5,
respectively, N¼ 5, Po0.05). In that context, AMT gave
the best results, with 69 and 51% reduction when compared
to MMF or Xi, respectively (P¼ 0.004 between groups).
qPCR data for MCP-1 mRNA levels revealed that MMF and
Xi-treated mice presented low levels of MCP-1 24 h after the
procedure (2.3±1.6 and 3.7±1.2 fold change, respectively,
N¼ 5, Po0.05), due to effective immunosuppression, versus
12.9±0.9 fold change in AMT-treated obstructed kidneys
and 13.0±1.9 fold change in nontreated obstructed kidneys.
Of note, during the progression of renal injury induced by
UUO, MMF and Xi groups presented an increase in MCP-1
levels. This increment on MCP-1 expression was still
significantly reduced in MMF-treated mice (20.1±2.8 fold
change at day 5, Po0.05; Figure 7c). Xi mice did not show
any difference between nontreated group (P¼ 0.811),
whereas AMT group showed the lowest level of that gene,
however, without significance when compared to MMF and
Xi (P¼ 0.375). Analysis of ICAM-1 gene expression (Figure
7d) demonstrated a blockade induced by MMF and Xi
(7.3±1.3 and 8.6±1.4 fold change at day 5, respectively,
N¼ 5, P¼ 0.01), without statistical differences between the
treatments (P¼ 0.318).
DISCUSSION
Progression of renal fibrosis induced by ureteral obstruction
is characterized by a significant increase in expression of
several molecules, including TGF-b1. It is well described that
TGF-b1 enhances extracellular matrix protein synthesis
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Figure 3 | Macrophage infiltration. Representative macrophage (CD-68 positive) infiltration in contralateral kidneys, nontreated obstructed
kidneys (UUO), and amitriptyline-treated obstructed kidneys (UUOþAMT) after 1, 3, 5, or 10 days of the procedure. Each image was
randomly acquired from the cortex area and is representative for five animals. Original magnification  200.
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Figure 4 | Gene expression analysis. qPCR for TGF-b1 (a), osteopontin (b), MCP-1 (c), and ICAM-1 (d) in nontreated obstructed kidneys
(UUO) and amitriptyline-treated obstructed kidneys (UUOþAMT). Data expressed as mRNA expression relation between obstructed/
contralateral kidneys. Each bar represents the mean±s.e.m. for at least five mice (*Po0.05, **Po0.01).
UUO AMT
XiMMF
Figure 5 | a-Smooth muscle actin expression. Representative interstitial a-smooth muscle actin expression in nontreated obstructed
kidneys (UUO), amitriptyline-treated obstructed kidneys (UUOþAMT), mycophenolate mofetil-treated obstructed kidneys (UUOþMMF),
and X-irradiated obstructed kidneys (UUOþXI), after 5 days of the procedure. Each image was randomly acquired from the cortex area and
is representative for five animals. Original magnification  200.
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and deposition within interstitium.26 TGF-b1 is also involved
in epithelial–mesenchymal transdifferentiation, increasing
expression of aSMA.27,28 It is well established that UUO
induce the expression of the mentioned inflammatory
mediators. As we observed inhibition of inflammatory
response after AMT administration in UUO model, we
proposed that AMT could attenuate renal injury induced by
ureteral obstruction through inhibition of genes involved in
development and progression of interstitial fibrosis. As
demonstrated in Figure 4a, obstructed kidneys significantly
express high levels of TGF-b1 and administration of AMT
reduced the expression of that profibrogenic cytokine.
However, during the first days of injury AMT did not change
TGF-b1 expression induced by UUO, which might explain
the slight expression of aSMA observed after AMT treatment
(Figure 2). We also tested the hypothesis that AMT could
modulate epithelial–mesenchymal transdifferentiation. We
employed human proximal tubular cells culture and AMT
administration did not change aSMA expression induced by
TGF-b1 (data not shown). Of note, in the unilateral ureteral
ligation model, TGF-b1 is released mainly by tubular
epithelial cells29 and directly affects macrophages infiltration
within interstitium.30 As we observed, AMT significantly
downregulated TGF-b1 and that could explain the inhibition
of macrophage infiltration in this experimental model.
Several mechanisms seemed to be related to the reduction
of macrophage infiltration. To better understand the
mechanisms of AMT blockade on interstitial inflammation,
Table 1 | Semiquantitative analysis of a-smooth muscle actin
expression
Myofibroblast (a-smooth muscle actin)
Obstructed kidney (days) Contralateral (days)
1 3 5 1 3 5
UUO +/++ ++ ++/+++ + + +
UUO+AMT + + + + + +
UUO+MMF + + 0/+ + + 0/+
UUO+Xi + + + + + 0/+
AMT, amitriptyline; MMF, mycophenolate mofetil; UUO, urinary unilateral obstruc-
tion; Xi, whole body X-irradiation.
Semi-quantitative analysis was performed by an independent pathologist. Expres-
sion of a-smooth muscle actin was scored as: rare (0), minimal (+), moderate (++)
and intense (+++). At least 5 samples were processed for analysis.
UUO AMT
XiMMF
Figure 6 | Macrophage infiltration. Representative macrophage (CD-68 positive) infiltration in nontreated obstructed kidneys (UUO),
amitriptyline-treated obstructed kidneys (UUOþAMT), mycophenolate mofetil-treated obstructed kidneys (UUOþMMF), and X-irradiated
obstructed kidneys (UUOþXI), after 5 days of the procedure. Each image was randomly acquired from the cortex area and is representative
for five animals. Original magnification  200.
Table 2 | Semiquantitative analysis of macrophage infiltration
Macrophage infiltration (CD68+)
Obstructed kidney (days) Contralateral (days)
1 3 5 1 3 5
UUO ++ ++/+++ +++ 0/+ + 0/+
UUO+AMT + + + + + +
UUO+MMF + + + + 0/+ +
UUO+Xi + + + + + +
AMT, amitriptyline; MMF, mycophenolate mofetil; UUO, urinary unilateral obstruc-
tion; Xi, whole body X-irradiation.
Semi-quantitative analysis was performed by an independent pathologist. Expres-
sion of CD-68 was scored as: rare (0), minimal (+), moderate (++), and intense (+++).
At least five samples were processed for analysis.
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we examined the mRNA levels of the typical macrophage
chemokines osteopontin, MCP-1, and ICAM-1 by qPCR.
Osteopontin is a phosphoprotein produced by the kidney
that mediates cell adhesion and migration. Knockout mice
studies demonstrated that osteopontin is a critical factor for
interstitial macrophage accumulation.31 As seen in Figure 4b,
UUO promoted a significant time-dependent increase in
osteopontin mRNA expression and that was suppressed by
AMT treatment.
The most impressive data were obtained when we analyzed
MCP-1 gene expression. Kitagawa et al.7 demonstrated that
MCP-1-deficient mice in CCR2 have attenuated tubular
injury with a reduction in the expression of MCP-1, TGF-b,
and collagen, and less infiltration of macrophages in the
region and interstitial glomerular. In our experimental
model, UUO promoted a significant increase of MCP-1
levels. Of interest, AMT treatment decreased MCP-1 expres-
sion at day 5 and almost abolished it at day 10, which could
explain the effect of AMT in the inhibition of macrophage
infiltration (Figure 3). It also deserves consideration the fact
that Wolf et al.32 have proposed a relation between MCP-1
and TGF-b1 in renal injury independent of macrophage
recruitment. Thus, it is conceivable that AMT, through MCP-
1 downregulation, avoid modulation on extracellular matrix
compounds production by fibroblasts and activation of
tubular cells to transdifferentiate into fibroblast-like cells.
In addition, we analyzed ICAM-1 expression along AMT
treatment. ICAM-1 plays an important role in inflammatory
processes and, in normal conditions, is constitutively
expressed by capillary endothelial cells, glomerular mesangial
cells, and renal tubular epithelial cells.33 However, in response
to stimuli from inflammatory mediators, expression of
ICAM-1 can be markedly upregulated in mesangial and
epithelial cells of the kidney.34 AMT treatment also promoted
a significant inhibition of ICAM-1 gene expression after
ureteral obstruction. Although ICAM-1 by itself probably
does not elicit an inflammatory response, decreased ICAM-1
expression might contribute to the benefic effect of AMT on
interstitial fibrosis.
In this study, we found that administration of AMT
ameliorates tubulointerstitial fibrosis developed after UUO.
Macrophage infiltration, one of the key mechanisms involved
in the progression of interstitial fibrosis, was suppressed by
AMT. To highlight the effects of AMT in inhibiting
macrophage infiltration, we compared its effects to MMF
or Xi. The sublethal method of Xi employed in our study
gives a reproducible transient monocytopenia and reduction
in the renal macrophage number. MMF is an immuno-
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Figure 7 | Gene expression analysis. qPCR for TGF-b1 (a), osteopontin (b), MCP-1 (c), and ICAM-1 (d) in contralateral kidneys, nontreated
obstructed kidneys (UUO), amitriptyline-treated obstructed kidneys (AMT), mycophenolate mofetil-treated obstructed kidneys (MMF), and
X-irradiated obstructed kidneys (Xi), after 5 days of the procedure. Data expressed as mRNA expression relation between obstructed/
contralateral kidneys. Each bar represents the mean±s.e.m. for at least five mice (*Po0.05 and **Po0.01 vs nontreated obstructed kidneys,
#Po0.01 between treatments).
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suppressive agent that blocks the proliferation of activated B
cells and T cells and decreases the expression of adhesion
molecules.35 It has been used widely with solid organ
transplantation to prevent or reverse acute rejection.36
Mycophenolic acid, the active metabolite of MMF, has been
shown to inhibit the expression of adhesion molecules and
the production of lymphocyte- and macrophage-derived
cytokines and growth factors such as TGF-b1 and tumor
necrosis factor-a.37 Of interest, MMF has an anti-inflamma-
tory effect mediated by inhibition of the production
of lymphocyte and macrophage-derived growth factor
TGF-b138 and also attenuates the progression of the
fibrogenic process of UUO.10
Our data suggest that AMT might present better results of
gene expression profile when compared to MMF adminis-
tration or Xi (Figure 7). Although a weak signal is observed
in animals treated with AMT, the fact that an antidepressive
drug is able to avoid macrophage infiltration (when
compared to nontreated obstructed kidneys) is of relevance
to raise the possibility of using AMT to treat tubulointer-
stitial fibrosis and several other related injuries. All
treatments successfully ameliorated the progression of renal
injury induced by UUO. However, AMT takes advantage of
MMF and Xi when cost and side effects were concerned.
Of note, AMT also elicited other effects. For instance,
analgesia induced by AMT may account for some beneficial
effects observed after UUO. Mice were active and did not lose
appetite or weight, differently from nontreated mice. Tanda
et al.39 have recently demonstrated that histamine ameliorates
antiglomerular basement membrane antibody-induced glo-
merulonephritis in rats, possibly due to immunomodulatory
effects of H4 receptor agonism. Noteworthy, our findings
suggest that the anti-inflammatory properties of AMT are
independent of its antagonism on histaminergic receptors.
In conclusion, in this model of renal interstitial fibrosis,
AMT significantly attenuated interstitial inflammation and
fibrosis. These anti-inflammatory effects are greatly explained
by the downregulation in osteopontin, MCP-1, and ICAM-1,
and the decrease in interstitial fibrosis appears to result from
less severe tubular phenotypical changes, myofibroblast
differentiation, and renal TGF-b1 downregulation. We are
currently engaged in define the cellular and molecular
mechanisms involved in AMT blockade on interstitial fibrosis
and inflammation. Due to the considerable number of
patients treated with AMT in the past decades, its
pharmacokinetics and adverse effect profiles are well
recognized. Taken together, these elements suggest that
AMT can be a potential candidate in the treatment of
chronic renal disease.
MATERIALS AND METHODS
Urinary unilateral obstruction
Urinary unilateral obstruction model was induced in adult
male C57BL/6 mice (3–5 months, 20–25 g) under pentobar-
bital-induced anesthesia. The right ureter was ligated with
4-0 silk at two locations and cut between ligatures to prevent
urinary tract infection (obstructed kidney). Mice were given
AMT (1 mg/Kg body weight/day; Merck Sharp Dhome
Laboratories, Sa˜o Paulo, Brazil) or saline solution by daily
gastric gavage. Additional groups of mice with UUO (n¼ 4–6
per timepoint) received MMF (10 mg/Kg body weight/day;
Sigma-Aldrich, St Louis, MO, USA) by daily gastric gavage or
a solitary 6-Gy dose of whole body Xi, from a cobalt source
(Discipline of Radiology, Federal University of Sa˜o Paulo),
with bilateral kidney shielding,40 7 days before ureteral
ligation. Both obstructed and contralateral kidneys were
harvested 1, 3, 5, or 10 days after surgery and either snap
frozen in liquid nitrogen or fixed in buffered formalin. All
procedures were approved by the Ethics Committee on
Research from Federal University of Sao Paulo.
Immunohistochemistry
Kidneys fixed in buffered formalin were embedded in
paraffin, sectioned (4mm thick), and immunohistochemistry
or Masson’s trichrome stain (Sigma-Aldrich) were
performed. The slides were processed for identification of
macrophage infiltration (anti-CD68, clone KP1; Dako
Cytomation, Carpinteria, CA, USA) and myofibroblast
differentiation (anti-a-smooth muscle actin antibody, clone
HHF35; Dako Cytomation), followed by diaminobenzidine
detection system (Sigma-Aldrich). All samples were evaluated
with an Olympus IX51 microscope (Olympus Inc., Miami,
FL, USA). Images were acquired using a DP70 Digital
Camera (Olympus Inc.) associated with DP Controller v1.2
software (Olympus Inc.). The semiquantitative evaluation of
macrophagic population and interstitial myofibroblastic was
done by and independent pathologist.
Quantitative real-time PCR analysis
RNA was extracted from crushed frozen tissue by homo-
genization in Trizol (Invitrogen, Carlsbad, CA, USA), and
after DNAseI treatment and inhibition (Amersham Bios-
ciences, Piscataway, NJ, USA), 1 mg-aliquots of RNA were
used in a reverse transcription reaction with Improm-II
reverse transcriptase (Promega, Madison, WI, USA). The
resulting cDNA was used as template for qPCR analysis.
Primers were obtained from Invitrogen. GAPDH:
50-ACCACAGTCCATGCCATCAC-30 (sense), 50-TCCACCAC
CCTGTTGCTGTA-30 (antisense); ICAM-1: 50-GTGATGCTC
AGGTATCCATCCA-30 (sense), 50-CACAGTTCTCAAAGCAC
AGCG-30 (antisense); MCP-1: 50-TTAACGCCCCACTCAC
CTGCTG-30 (sense), 50-GCTTCTTTGGGACACCTGCTGC-30
(antisense); osteopontin: 50-TAGCTTGGCTTATGGACTGA
GG-30 (sense), 50-AGACTCACCGCTCTTCATGTG-30 (anti-
sense); TGF-b1: 50-ATCCTGTCCAAACTAAGGCTCG-30
(sense), 50-ACCTCTTTAGCATAGTAGTCCGC-30 (anti-
sense). Gene quantification was performed in duplicate on
the Applied Biosystems 7700 Real-Time PCR System
(Applied Biosystems, Warrington, UK). Quantification was
obtained from a dilutional standard curve from a given
sample. Data were normalized by GAPDH values, ratios
between obstructed and contralateral kidneys were log2-
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transformed (for linearization) and conventional paired ‘t’
tests or ANOVA were performed. Results were expressed as
fold changes in a log scale for convenience. Specificity of each
reaction was confirmed by dissociation curve and electro-
phoresis.
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